ReviewDiabetes, obesity & metabolism2026
Incretin-Based Therapies as Cardiometabolic Interventions: Outcome Hierarchy, Receptor-Network Pharmacology and Phenotype-Based Clinical Positioning.
Review in Diabetes, obesity & metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Incretin-Based Therapies as Cardiometabolic Interventions: Outcome Hierarchy, Receptor-Network Pharmacology and Phenotype-Based Clinical Positioning.Diabetes, obesity & metabolism · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
aimsIncretin-based pharmacotherapy was initially developed to improve glucose-dependent insulin secretion and glycaemic control in type 2 diabetes, but its clinical interpretation has expanded substantially with cardiovascular outcome trials, kidney outcome data, obesity studies and next-generation polyagonist development. This narrative clinical review uses structured literature identification and outcome-stratified synthesis to evaluate incretin-based therapies as cardiometabolic interventions across diabetes, obesity, cardiovascular disease and chronic kidney disease. MATERIALS AND
methodsThe available evidence was interpreted according to therapeutic class, clinical domain, outcome maturity and safety boundaries, integrating clinical outcome evidence with receptor-network pharmacology.
resultsSelected GLP-1 receptor agonists are supported by hard cardiovascular and renal outcome data, whereas several dual, triple, amylin-linked and oral small-molecule strategies are currently supported mainly by glycaemic, weight-loss, metabolic or early translational endpoints. This distinction is clinically important because treatment positioning should depend on patient phenotype, outcome maturity and safety boundaries rather than mechanistic plausibility alone. In patients with type 2 diabetes and established atherosclerotic cardiovascular disease, GLP-1 receptor agonists with proven cardiovascular outcome benefit should be prioritised when atherosclerotic risk reduction is a major treatment goal. In type 2 diabetes with chronic kidney disease, semaglutide has dedicated kidney outcome evidence. In obesity with cardiometabolic risk, high-magnitude and sustained weight reduction has become a clinically relevant therapeutic target. Receptor-network pharmacology, including GLP-1, GIP, glucagon and amylin receptor signalling, provides a useful explanatory framework for heterogeneous efficacy, tolerability and tissue-level effects.
conclusionsHowever, clinical use remains bounded by gastrointestinal tolerability, lean-mass preservation, treatment durability, discontinuation effects and long-term safety. This review therefore proposes phenotype-based clinical positioning rather than a prescriptive treatment algorithm.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.